Assessment Status | Rapid Review Complete |
HTA ID | 25040 |
Drug | Acalabrutinib |
Brand | Calquence® |
Indication | Acalabrutinib is indicated in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). |
Assessment Process | |
Rapid review commissioned | 30/06/2025 |
Rapid review completed | 16/07/2025 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of acalabrutinib compared with the current standard of care. |
*The Applicant is seeking reimbursement for a subpopulation of the licensed population, specifically for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia excluding those with del(17p)/TP53 mutation.